Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience [PDF]
AntibioticsAcute Bacterial Skin and Skin Structure Infections (ABSSSI) are marked by substantial morbidity, frequent need for hospitalization, and long courses of intravenous antibiotic therapy. Herein, we report four cases of pediatric patients admitted for ABSSSI
Sara Maria Scarano +5 more
doaj +2 more sources
The future approach for the management of acute bacterial skin and skin structure infections. [PDF]
Curr Opin Infect DisPurpose of review To discuss the new available options for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and how to implement in the clinical practice innovative approaches for their management.
Tiseo G, Falcone M.
europepmc +3 more sources
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis [PDF]
BMC Infectious Diseases, 2021 Background Delafloxacin is a novel fluoroquinolone with broad antibacterial activity against pathogens causing acute bacterial skin and skin structure infections (ABSSSI).
Ioanna Vlachaki +6 more
doaj +2 more sources
Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections. [PDF]
J Pharm Technol, 2019 Objective: To review the microbiological activity, safety, and efficacy of the new fluoroquinolone delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Data Sources: A PubMed search from 1945 to September 2018 was done using the terms delafloxacin, acute bacterial skin and skin structure infections, skin and ...
Lee YR, Burton CE, Bevel KR.
europepmc +4 more sources
Infection and Drug Resistance, 2018 Elda Righi, Alessia Carnelutti, Antonio Vena, Matteo Bassetti Infectious Diseases Division, Santa Maria della Misericordia University Hospital, Udine, Italy Abstract: The increase in hospitalization due to acute bacterial skin and skin ...
Righi E +3 more
doaj +5 more sources
Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. [PDF]
J Antimicrob ChemotherAbstract Objectives Lefamulin is a pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP). Its spectrum of activity, good penetration into soft tissues and low rates of cross-resistance also make lefamulin a potentially valuable option for treatment of ...
van Os W, Zeitlinger M.
europepmc +3 more sources
Journal of Pharmacy and Bioallied Sciences, 2020 Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity and mortality in hospitalized patients and outpatients as well.
Syed Bilal Tanvir +4 more
doaj +2 more sources
Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. [PDF]
Clin Infect Dis, 2019 Corey GR, McKinnell JA, Rybak MJ.
europepmc +4 more sources
Tackling Extended Hospital Stays in Patients with Acute Bacterial Skin and Skin Structure Infections
European Medical Journal, 2022 Hospitalisation rates for acute bacterial skin and skin structure infection (ABSSSI) are rising and represent a large pharmacoeconomic burden as treatment may involve an extended number of days of antibiotic therapy. This article first aims to provide a
Gavin Barlow +2 more
doaj +1 more source
Oritavancin for acute bacterial skin and skin structure infections [PDF]
Expert Opinion on Pharmacotherapy, 2015 Inpatient treatment of acute bacterial skin and skin structure infections (ABSSSIs) exerts a significant economic burden on the healthcare system. Oritavancin is a concentration-dependent, rapid bactericidal agent approved for the treatment of ABSSSIs.
Julia A, Messina +2 more
openaire +5 more sources